BridgeMD
Study with Enzalutamide to understand molecular alterations in prostate cancer
EU CTIS ID: 2024-514786-19-01
What this study is testing
To study the molecular and cellular changes caused by Enzalutamide treatment as measured by receptor activity before and after Enzalutamide treatment.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age over 18 years at the time of signing the informed consent form
- Patients diagnosed with localized high-risk prostate cancer in whom radical prostatectomy indicated.
- Patients who decide surgery as curative intent for their pathology
- Patients who sign the IC prior to any study-related activity, including the necessary screening evaluations
You likely can't join if
- Patients diagnosed with non-high risk prostate cancer.
- Men with pregnant partners who do not commit in writing to use a condom during the study and for up to 3 months afterwards
- Patients who do not sign the informed consent form
- Patients who are not going to undergo radical prostatectomy with robotic assistance.
- Patients with active cancer in any other location
- Diagnosis of any other pathology that in the investigator's opinion may increase the subject's risk or reduce the chances of obtaining satisfactory data to achieve the objectives of the study, including the consumption of alcohol or any other drug.
See the full eligibility criteria
- Age over 18 years at the time of signing the informed consent form
- Patients diagnosed with localized high-risk prostate cancer in whom radical prostatectomy indicated.
- Patients who decide surgery as curative intent for their pathology
- Patients who sign the IC prior to any study-related activity, including the necessary screening evaluations
- Patients diagnosed with non-high risk prostate cancer.
- Men with pregnant partners who do not commit in writing to use a condom during the study and for up to 3 months afterwards
- Patients who do not sign the informed consent form
- Patients who are not going to undergo radical prostatectomy with robotic assistance.
- Patients with active cancer in any other location
- Diagnosis of any other pathology that in the investigator's opinion may increase the subject's risk or reduce the chances of obtaining satisfactory data to achieve the objectives of the study, including the consumption of alcohol or any other drug.
- Having received previous treatment with hormones, Finasteride or Dutasteride before signing the informed consent
- Contraindication due to potential interactions of their usual treatment with Enzalutamide or for any other cause in the investigator's judgment such as difficulty swallowing
- Inability to initiate treatment within the first week after signing the consent
- Participation in another clinical trial where they have received an investigational drug in the 6 months prior to signing the informed consent
- Men with partners physiologically capable of becoming pregnant who do not commit in writing to use, during their participation in the study and up to 3 months after the end of the study, a reliable method of contraception. Men must also use a condom-type barrier method for the same period of time
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.